TABLE 2

Antiproliferative activity of CGP57380, MNKI-19, and MNKI-85 in leukemia cell lines with various FLT3 mutational statuses and normal fibroblast cells by 72-hour resazurin and MTT assays, respectively

Cell Line	FLT3 Status	FAB Subtype	72-hour GI₅₀ (µM)^{^a} ± S.D.
Cell Line	FLT3 Status	FAB Subtype	CGP57380	MNKI-19	MNKI-85
MOLM-13	ITD	M5a	8.81 ± 0.80	5.65 ± 0.84	7.19 ± 0.08
MV4-11	ITD	M5	6.89 ± 0.16	7.30 ± 0.75	7.44 ± 0.77
PL-21	ITD/WT	M3	9.39 ± 0.11	57.17 ± 6.74	>100
HL-60	WT	M2	16.83 ± 1.98	69.18 ± 6.15	>100
THP-1	WT	M5	38.97 ± 2.98	>100	94.06 ± 8.40
U937	WT	M4/5	9.40 ± 0.60	33.59 ± 4.21	>100
K562	WT	(CML)	34.13 ± 1.82	93.16 ± 9.68	>100
WI-38^b	Normal fibroblast cells	Normal fibroblast cells	62.37 ± 0.24	98.63 ± 1.54	43.40 ± 5.05

CML, chronic myeloid leukemia; FAB, French-American-British classification system.
↵^a Data shown are the mean values derived from at least two replicates ± S.D.
↵^b The GI₅₀ values were determined by 72-hour MTT assay.